Molecular Product Management is a startup focused on diabetic peripheral neuropathy (DPN), the nerve and microvascular damage that causes chronic pain, burning and numbness. Our breakthrough therapy treats nerve damage itself,, unlike current drugs that only kill pain and have serious side effects.
At a time when Type 2 diabetes is a global epidemic and 50% of all sufferers develop some degree of DPN, we are answering a vast and unmet need to substantially improve patients' lives. By addressing a core condition, our drug also will deliver value, reducing DPN's long-term social and medical costs.
MPM plans to put our drug on an accelerated FDA path through early trials, enabling exit via acquisition in 3-4 years. MPM holds exclusivity and we think the pharma M&A space has great demand for innovative DPN therapies.
Company Details
- Employees
- 2
- Founded
- 2015
- Address
- 308 W 103rd St,
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Keywords
- Biotech, Diabetic neuropathy, Seed startup.
- HQ
- New York, New York
Molecular Product Management Llc Questions
Molecular Product Management Llc's LinkedIn profile is https://www.linkedin.com/company/molecular-product-management
Molecular Product Management Llc has
2 employees.
View email and phone details for 2
employees at Molecular Product Management Llc.
Molecular Product Management Llc's industry is
Pharmaceutical Manufacturing
Molecular Product Management Llc's top competitors are
Waveacid Inc.,
Vartest Laboratories,
Smart Pharmaceutical Consulting (Spc),
Cleftalign, Inc.,
Tresler Group,
John Hosier Healthcare Consulting, Llc,
Pharmpay Global, Llc.,
Delphine Diagnostics Inc,
Inventure, Llc,
Cardiomo.
Molecular Product Management Llc's categories are Pharmaceutical Manufacturing
Molecular Product Management Llc's founding year is 2015
